---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-098068"
form_type: "8-K"
ticker: "SRTS"
cik: "0001494891"
company_name: "Sensus Healthcare, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:25:32.730763+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensus Healthcare Q3 2024 revenue doubles to $8.8M; net income of $0.07 per diluted share

## Summary
- Revenue $8.8M (+127% YoY); net income $1.2M vs net loss $1.5M in Q3 2023.
- Shipped 27 systems (11 in Q3 2023); cash $22.6M, no debt.
- Adjusted EBITDA $1.6M (negative $1.7M a year ago).
- Signed Fair Deal Agreement with Platinum Dermatology (130+ clinics); 22 agreements since March 2024.
- Sold SRT system to Providence Swedish Hospital; expects recurring revenue from Fair Deal Agreements in 2025.

## SEC filing metadata
- accession: 0001213900-24-098068
- form_type: 8-K
- ticker: SRTS
- cik: 0001494891
- company_name: Sensus Healthcare, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494891/000121390024098068/0001213900-24-098068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494891/000121390024098068/ea0221149-8k_sensus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-098068
- JSON: https://secwatch.observer/filing/0001213900-24-098068.json
- Plain text: https://secwatch.observer/filing/0001213900-24-098068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.